VC interest remains strong in European life sciences

Despite market volatility, regulatory unknowns, and geopolitical headwinds, Europe’s life sciences sector is seeing sustained VC confidence. While overall deal volume is down, capital is flowing into fewer but bolder bets—focused on later-stage biotechs with differentiated assets, compelling data, and experienced leadership.

C-suite decision-makers should note that investors are broadening their interests beyond oncology and obesity to include neurodegeneration, autoimmune disease, and next-gen platforms in RNA, cell therapy, and AI-driven drug development. Funds are increasingly backing innovation enablers as well as therapeutics—particularly those addressing bottlenecks in manufacturing or accelerating time to clinic.

The message is clear: while the bar for funding has never been higher, the cheques have never been bigger for those who meet it. Selectivity is in, but so is ambition.

Read the full analysis and explore where capital is heading next.